TerrAscend Corp. (OTCMKTS:TSNDF - Free Report) - Stock analysts at Atb Cap Markets dropped their FY2024 earnings per share (EPS) estimates for TerrAscend in a research report issued to clients and investors on Wednesday, November 6th. Atb Cap Markets analyst F. Gomes now forecasts that the company will earn ($0.20) per share for the year, down from their prior forecast of ($0.14). The consensus estimate for TerrAscend's current full-year earnings is ($0.14) per share. Atb Cap Markets also issued estimates for TerrAscend's Q4 2024 earnings at ($0.03) EPS and FY2025 earnings at ($0.09) EPS.
Separately, Ventum Cap Mkts raised TerrAscend to a "strong-buy" rating in a research note on Friday, August 9th.
Get Our Latest Stock Report on TSNDF
TerrAscend Stock Down 27.2 %
TSNDF traded down $0.25 during trading on Monday, reaching $0.67. The stock had a trading volume of 865,629 shares, compared to its average volume of 346,856. The stock's 50 day moving average is $1.16 and its two-hundred day moving average is $1.36. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.35 and a quick ratio of 0.69. TerrAscend has a one year low of $0.67 and a one year high of $2.45.
TerrAscend (OTCMKTS:TSNDF - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). The firm had revenue of $77.52 million during the quarter, compared to the consensus estimate of $80.70 million. TerrAscend had a negative return on equity of 31.48% and a negative net margin of 23.95%.
TerrAscend Company Profile
(
Get Free Report)
TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures vaporizables, concentrates, topicals, tinctures and edibles. It also operates retail dispensaries under the Apothecarium and State Flower brand names.
Further Reading
Before you consider TerrAscend, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TerrAscend wasn't on the list.
While TerrAscend currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
